Ariad Pharm (NASDAQ:ARIA) has been downgraded from Buy to Hold in a statement by SunTrust today.
- Updated: January 11, 2017
Just yesterday Ariad Pharm (NASDAQ:ARIA) traded 0.08% higher at $23.68. Ariad Pharm’s 50-day moving average is $12.93 and its 200-day moving average is $10.88. The last closing price is up 117.89% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.04% over the same time period. 2,254,310 shares of ARIA traded hands, down from an average trading volume of 6,542,560
SunTrust has downgraded Ariad Pharm (NASDAQ:ARIA) from Buy to Hold in a statement released on 01/11/2017.
Recent Performance Chart
Ariad Pharm has 52 week low of $4.37 and a 52 week high of $23.71 and has a market capitalization of $0.
In addition to SunTrust reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $9.00 with 2 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 5 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Ariad Pharm (NASDAQ:ARIA)
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.